ArticleTherapeutic advances in musculoskeletal disease2020
Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey.
Article in Therapeutic advances in musculoskeletal disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Combination of dual-energy CT findings and clinical features predicts risk of frequent flares of gout.European radiology · 2026Article
- Knowledge, attitudes, and practices regarding gout management among patients in Xiamen, China: a cross-sectional study.Frontiers in public health · 2026Article
- Assessment of drug induced hyperuricemia and gout risk using the FDA adverse event reporting system.Scientific reports · 2025Article
- Determinants of Self-Management Behavior in Gout: A Scoping Review.Arthritis care & research · 2025Article
- The Status Quo and Influencing Factors of Self-Management Behavior in Patients with Recurrent Gout in China: A Cross-Sectional Study.Patient preference and adherence · 2025Article
- Self-management behavior preferences and influencing factors in Chinese patients with recurrent gout: A qualitative study.International journal of nursing sciences · 2024Article
- Harnessing Nanotechnology for Gout Therapy: Colchicine-Loaded Nanoparticles Regulate Macrophage Polarization and Reduce Inflammation.Biomaterials research · 2024Article
- Development and validation of a prediction nomogram for depressive symptoms in gout patients.Frontiers in public health · 2024Article
- Changes in the mean incidence and variance of orthopedic diseases before and during the COVID-19 pandemic in Korea: a retrospective study.BMC musculoskeletal disorders · 2023Article
- Association between smoking behavior and serum uric acid among the adults: Findings from a national cross-sectional study.PloS one · 2023Article
- Rapid Review of Medication Taking (Adherence) Among Patients With Rheumatic Diseases During the COVID-19 Pandemic.Arthritis care & research · 2022Article
- Relationship between hyperuricemia with deposition and sexual dysfunction in males and females.Journal of endocrinological investigation · 2022Review
- Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement.Clinical rheumatology · 2022Article
- A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Article
- Gout management and outcomes during established COVID-19 pandemic in 2020-2021: a cross-sectional Internet survey.Therapeutic advances in musculoskeletal disease · 2022Article
- The effect of COVID-19 public health restrictions on the health of people with musculoskeletal conditions and symptoms: the CONTAIN study.Rheumatology (Oxford, England) · 2021Article
- Patients with gout: an under-recognised group at high risk of COVID-19.The Lancet. Rheumatology · 2021Article
- Second-Hand Smoke and Its Synergistic Effect with a Body-Mass Index of >24.9 kg/mInternational journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimWe aimed to assess the gout management during the COVID-19 pandemic.
methodsWe assessed medication use, healthcare utilization, gout-specific health-related quality of life (HRQoL) on the Gout Impact Scale (GIS), psychological distress using the patient health questionnaire-4 (PHQ-4), and resilience in people with self-reported physician-diagnosed gout during the COVID-19 pandemic in a cross-sectional Internet survey.
resultsAmong the 122 survey respondents with physician-diagnosed gout, 82% were prescribed urate-lowering therapy (ULT) and 66% were taking ULT daily; mean age was 54.2 years [standard deviation (SD), 13.8], 65% were male, and 79% were White. More regular use of gout medication was reported during the COVID-19 pandemic: allopurinol, 44%; colchicine, 37%; non-steroidal anti-inflammatory drugs, 36%. Gout flares were common: 63% had ⩾1 gout flare monthly; 11% went to emergency room/urgent care; and 2% were hospitalized with gout flares. Between 41% and 56% of respondents reported more difficulty with gout management and related functional status related to COVID-19; 17-37% had difficulty with healthcare access for gout. HRQOL deficits were evident for gout concern overall, 79.4 (SD, 25); unmet gout treatment need, 64.5 (SD, 27.1); and gout concern during flare, 67.3 (SD, 27.1); but less so for gout medication side effects, 48.9 (SD, 27.4). Psychological distress was moderate in 19% and severe in 15% (mild, 22%; normal, 45%). Resilience score on Connor-Davidson Resilience Scale (CD-RISC2) was 5.6 (SD, 1.8; range 0-8). Compared with no/mild psychological distress, moderate-severe psychological distress during the COVID-19 pandemic was significantly associated with more difficulty getting gout medication filled (
conclusionHealthcare gaps, psychological distress, and HRQoL deficits were commonly reported by people with gout during the COVID-19 pandemic. Interventions to address these challenges for people with gout during the COVID-19 pandemic are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.